Shares of Axsome Therapeutics were up in the premarket on Wednesday after the company announced that the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for patients with the sleeping disorder narcolepsy The neurology dru
Shares of Axsome Therapeutics were up in the premarket on Wednesday after the company announced that the U.S.
FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for patients with the sleeping disorder narcolepsy
The neurology drug developerâs
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
